Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025958 | 0.89 | ALDH1A1 (0.59) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL10005923 | 0.78 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Carmustine SCHEMBL2047318 | 0.76 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Carmustine SCHEMBL4503 | 0.76 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Elmustine SCHEMBL93476 | 0.74 | ALDH1A1 (0.82) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Fotemustine SCHEMBL16174560 | 0.73 | ALDH1A1 (0.44) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Fotemustine SCHEMBL8881 | 0.73 | ALDH1A1 (0.44) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Fotemustine SCHEMBL8880 | 0.73 | ALDH1A1 (0.44) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL11148427 | 0.72 | ALDH1A1 (0.72) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Fotemustine SCHEMBL7206688 | 0.72 | ALDH1A1 (0.43) | ALDH1A1BLMPMP22MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480655-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-12-01 | — | — | EP | claimed |
| WO-2003074060-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-09-12 | — | — | WO | claimed |
| WO-2008137207-A2 | INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1807438-A1 | BETA-GLUCURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006029065-A1 | BETA-GLUGURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | GOVERMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1480655-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074060-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-09-12 | — | — | WO | disclosed |
| EP-1054890-A1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2000-11-29 | — | — | EP | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999041269-A1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0868189-A4 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR INC (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0866712-A4 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR INC (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0868189-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0866712-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997018819-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE (-)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997018818-A1 | ANTINEOPLASTIC METHODS AND COMPOSITIONS EMPLOYING (+)-FOTEMUSTINE | SEPRACOR, INC. (US) | 1997-05-29 | — | — | WO | disclosed |